Abstract
Acute COVID-19 infection can be followed by diverse clinical manifestations referred to as Post Acute Sequelae of SARS-CoV2 Infection (PASC). Studies have shown an increased risk of being diagnosed with new-onset psychiatric disease following a diagnosis of acute COVID-19. However, it was unclear whether non-psychiatric PASC-associated manifestations (PASC-AMs) are associated with an increased risk of new-onset psychiatric disease following COVID-19.
A retrospective EHR cohort study of 1,603,767 individuals with acute COVID-19 was performed to evaluate whether non-psychiatric PASC-AMs are associated with new-onset psychiatric disease. Data were obtained from the National COVID Cohort Collaborative (N3C), which has EHR data from 65 clinical organizations. EHR codes were mapped to 151 non-psychiatric PASC-AMs recorded 28-120 days following SARS-CoV-2 diagnosis and before diagnosis of new-onset psychiatric disease. Association of newly diagnosed psychiatric disease with age, sex, race, pre-existing comorbidities, and PASC-AMs in seven categories was assessed by logistic regression.
There was a significant association between six categories and newly diagnosed anxiety, mood, and psychotic disorders, with odds ratios highest for cardiovascular (1.35, 1.27-1.42) PASC-AMs. Secondary analysis revealed that the proportions of 95 individual clinical features significantly differed between patients diagnosed with different psychiatric disorders.
Our study provides evidence for association between non-psychiatric PASC-AMs and the incidence of newly diagnosed psychiatric disease. Significant associations were found for features related to multiple organ systems. This information could prove useful in understanding risk stratification for new-onset psychiatric disease following COVID-19. Prospective studies are needed to corroborate these findings.
Funding NCATS U24 TR002306
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NCATS U24 TR002306.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was exempted by the Institutional Review Board (IRB) at the Jackson Laboratory under 45 CFR 46.101(b) (Common Rule). The N3C data transfer to the National Center for Advancing Translational Sciences (NCATS) is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵9 Champions Service, Computational Science Support Network, Multi-Tier Assistance, Training, and Computational Help (MATCH) Program, National Science Foundation Advanced Cyberinfrastructure Coordination Ecosystem: Services and Support (ACCESS), https://access-ci.org/
We made several adjustments to our main analysis of the correlation between PASC-AM categories and new-onset psychiatric diseases. We removed the outcome dementia from our analysis. We further adjusted the outcomes of anxiety, mood, and psychotic disorders to only include primary disorders for each. We then changed the outcome of any psychiatric disease to only include any of the three other outcomes. In the last submission we studied patients in the period of 21-120 days after COVID-19 diagnosis; we revised this to be 28-120 days. Additionally, we excluded PASC-AMs that were diagnosed on the same day as the new-onset psychiatric disease. As an additional analysis, we looked at the temporal relationship between PASC-AMs and new-onset psychiatric diseases. Figure 4 shows these results. Finally we did an additional sensitivity analysis by removing PASC-AMs which occurred within 10 days of the new-onset psychiatric disease.
Data Availability
The data presented in this paper can be accessed upon application to the NCATS N3C Data Enclave at https://covid.cd2h.org/enclave.
